Cencora, Inc. (COR)
NYSE: COR · Real-Time Price · USD
228.20
+0.56 (0.25%)
At close: Dec 24, 2024, 1:00 PM
226.50
-1.70 (-0.74%)
Pre-market: Dec 26, 2024, 7:13 AM EST
Cencora Revenue
In the fiscal year ending September 30, 2024, Cencora had annual revenue of $293.96B with 12.12% growth. Cencora had revenue of $79.05B in the quarter ending September 30, 2024, with 14.69% growth.
Revenue (ttm)
$293.96B
Revenue Growth
+12.12%
P/S Ratio
0.15
Revenue / Employee
$6,390,404
Employees
46,000
Market Cap
44.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 293.96B | 31.79B | 12.12% |
| Sep 30, 2023 | 262.17B | 23.59B | 9.89% |
| Sep 30, 2022 | 238.59B | 24.60B | 11.50% |
| Sep 30, 2021 | 213.99B | 24.09B | 12.69% |
| Sep 30, 2020 | 189.89B | 10.30B | 5.74% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CVS Health | 367.25B |
| McKesson | 330.19B |
| GSK | 41.97B |
| Takeda Pharmaceutical | 31.73B |
| Becton, Dickinson and Company | 20.18B |
| Haleon | 15.07B |
| Alcon | 9.76B |
| Agilent Technologies | 6.51B |
COR News
- 16 days ago - Cencora Closes $1.8 Billion Senior Notes Offering - Business Wire
- 19 days ago - Cencora Launches Accelerate Pharmacy Solutions to Enhance Support for Hospital and Health System Customers - Business Wire
- 20 days ago - Cencora: Competitive Advantages Defined - Seeking Alpha
- 23 days ago - Cencora Prices $500 Million 4.625% Senior Notes Due 2027, $600 Million 4.850% Senior Notes Due 2029 and $700 Million 5.150% Senior Notes Due 2035 - Business Wire
- 4 weeks ago - Cencora to Host Inaugural Product Showcase - Business Wire
- 7 weeks ago - Cencora Acquires Retina Care Practice Network For $4.6 Billion, Boosts Dividend On Better Than Expected Q4 Earnings - Benzinga
- 7 weeks ago - Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Cencora to buy Retina Consultants of America for $4.6 bln - Reuters